Related Experiment Videos
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment
David Raben1, Cataldo Bianco, Barb Helfrich
1University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Aurora 80010-0510, USA. david.raben@uchsc.edu
Abstract:
The introduction of biologically active agents that interfere with the epidermal growth factor receptor (EGFR) provides a promising opportunity to improve cancer treatment outcomes. Several EGFR-selective agents, such as humanized monoclonal antibodies and small molecule, orally available tyrosine kinase inhibitors have shown antitumor activity in early clinical trials in advanced cancer patients. Preclinical studies have demonstrated enhanced radiation- and chemotherapy-induced tumor cytotoxicity when EGFR antagonists are implemented. More broadly, recent clinical trials have confirmed improved survival with combinations of HER-2 (a member of the ErbB family of receptors) targeted antibodies and chemotherapy in patients with advanced breast cancer. A landmark trial combining C225 antiEGFR antibody with radiation therapy for patients with locally advanced head and neck cancer has just completed accrual. Thus, emerging rapidly are cancer treatment strategies based on an improved understanding of the specific cellular and molecular abnormalities of individual tumors.
Insights
Targeting the epidermal growth factor receptor (EGFR) with new agents shows promise for improving cancer treatment. Clinical trials demonstrate enhanced antitumor activity and survival benefits when using these targeted therapies alone or with chemotherapy and radiation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Biologically active agents targeting the epidermal growth factor receptor (EGFR) offer new therapeutic avenues for cancer treatment.
- EGFR-selective agents, including monoclonal antibodies and tyrosine kinase inhibitors, have demonstrated antitumor activity in clinical trials.
- Preclinical research indicates that EGFR antagonists can enhance the efficacy of radiation and chemotherapy.
Purpose of the Study:
- To review the emerging cancer treatment strategies based on targeting the epidermal growth factor receptor (EGFR).
- To highlight the clinical success of EGFR-targeted therapies and their combinations in various advanced cancers.
Main Methods:
- Review of early and recent clinical trials involving EGFR-selective agents.
- Analysis of preclinical studies on the combined effects of EGFR antagonists with radiation and chemotherapy.
- Examination of clinical trial data for HER-2 targeted antibodies and anti-EGFR antibodies in combination therapies.
Main Results:
- EGFR-selective agents have shown significant antitumor activity in advanced cancer patients.
- Combination therapies, such as HER-2 targeted antibodies with chemotherapy, have improved survival in breast cancer.
- A landmark trial combining an anti-EGFR antibody (C225) with radiation for head and neck cancer has completed.
Conclusions:
- Targeted cancer therapies based on specific tumor abnormalities are rapidly emerging.
- Interference with the epidermal growth factor receptor (EGFR) pathway represents a promising strategy for improving cancer treatment outcomes.
- Combination strategies involving targeted agents, chemotherapy, and radiation show significant potential for enhancing patient survival.